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Last but no least, I feel indebted to my parents for their support and love during
my studies and to my brother Milutin who was always near when I needed him. And
of course, I thank my friend Stanislav for his moral encouragement and listening to
my good and bad lab days even he does not understand a word.
iii
Abstract
Gag polyprotein is the precursor of HIV-1 structural proteins, required for correct
assembly, budding and maturation of viral particle within HIV-1 life cycle. The pro-
cess of maturation into an infectious virion is dependent on Gag and GagPol cleavage
at nine predefined sites by HIV-1 proteinase. Its disruption is one of the main targets
of HIV treatment. HIV-1, however, develops resistance to the proteinase inhibitors
by creating mutations in both the proteinase and the substrate.
The Gag processing by HIV-1 proteinase is a highly sequential process, that hap-
pens in specific order and rate. Previous biochemical studies determined the kinetic
data of these processes using oligopeptides representing naturally occuring cleavage
sites. This thesis describes the cleavage of the Gag polyprotein itself, which is the
natural substrate of HIV-1 proteinase. For this purpose, the full-length Gag polypro-
tein was recombinantly prepared in bacterial expression system. The cleavage was
carried out and its products were analyzed via SDS-PAGE and Western blotting.
The substrate specificity of the wild-type and mutant HIV-1 proteinase with respect
to the full-length wild-type Gag polyprotein was compared. Substantial differences
were observed between the rates of individual steps of cleavage by the wild-type and
mutant HIV-1 proteinase.
Key words: HIV, Gag, kinetics, proteinase, inhibitor, drug resistance
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Abstrakt
Polyprotein Gag je prekurzorem strukturńıch protein̊u viru HIV-1 nezbytných
pro správné složeńı, pučeńı a zráńı virové částice v pr̊uběhu životńıho cyklu viru
HIV-1. Proces zráńı do stádia infekčńıho virionu je závislý na štěpeńı polyproteinu
Gag a GagPol virovou proteinasou na dev́ıti přesně určených mı́stech. Narušeńı
tohoto štěpeńı je jedńım z hlavńıch terapeutických ćıl̊u v léčbě nákazy HIV. Virus
HIV-1 si však vytvář́ı rezistenci k inhibitor̊um proteinasy vznikem mutaćı jak v
proteinase samotné, tak v jej́ım substrátu.
Štěpeńı Gagu HIV-1 proteinasou je proces s přesně daným pořad́ım a rych-
lost́ı jednotlivých krok̊u. Předchoźı biochemické studie stanovily kinetické para-
metry těchto proces̊u s pomoćı oligopeptid̊u reprezentuj́ıćıch přirozeně se vysky-
tuj́ıćı štěpićı mı́sta. Tato práce popisuje štěpeńı samotného polyproteinu Gag, který
je přirozeným substrátem HIV-1 proteinasy. Za t́ımto účelem byl rekombinantně
připraven kompletńı polyprotein Gag v bakteriálńım expresńım systému. Bylo pro-
vedeno jeho štěpeńı HIV-1 proteinasou a produkty tohoto štěpeńı byly analyzovány
pomoćı SDS-PAGE a Western blotu. Dále byla porovnána substrátová specifita pro-
teinasy divokého typu a mutované varianty HIV-1 proteinasy v̊uči kompletńımu di-
vokému typu Gag polyproteinu. Byly pozorovány podstatné rozd́ıly mezi rychlostmi
jednotlivých krok̊u štěpeńı pomoćı proteinasy divokého typu a mutované HIV-1 pro-
teinasy.
Kl’́učové slová: HIV, Gag, kinetika, proteinasa, inhibitor, rezistence v̊uči léčivu
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Acquired Immunodeficiency Syndrome (AIDS) was described by Centers for Disease Con-
trol and Prevention (CDC) in July 1982. Soon, its causative agent was identified by team
of French scientists led by Luc Montagnier [1] and American scientists led by Robert
Charles Gallo [2]. The virus was named the Human Immunodeficiency Virus (HIV) by
the International Committee on Taxonomy of Viruses. There are two strains of HIV:
HIV-1 and HIV-2 [3]. They share 50% homology and differ in pathogenicity (the ratio of
infectivity HIV-1/HIV-2 is 3.6) and geographic location [4, 5].
HIV is a member of the Retroviridae family, genus lentivirus. The infection is usually
transmitted via sexual intercourse. The transmission via blood transfusion or from preg-
nant mother to her child was significantly decreased due to blood control and antiviral
therapy, respectively. HIV attacks human immune system and reduces the number of its
vital cells, in particular dendritic cells, macrophages and mainly CD4+ Th cells [6]. Thus
organism is unable to protect itself from various opportunistic infections and people die
due to immune system failure.
AIDS is still one of the most numbered lethal disease in the world. According to
World Health Organization (WHO), around 34 million people live with HIV and there
are 1.7 million deaths due to AIDS according to statistics of the HIV infection in 2011
[7]. Unfortunately and despite all the prevention work, the number of patients is still
increasing mainly in regions of subsaharian Africa.
10
The aim of the anti-HIV therapy is to significantly decrease the viral load and to
enhance patient’s immunity by increasing CD4+ cells. Patients are usually treated with
a highly active antiviral therapy (HAART), treatment that combines drugs of different
targets of the viral life cycle and inhibit HIV replication. This results in prolonged life
expectancy and decreased mortality of the patients.
Unfortunately, the virus is highly variable, and the mutations cause resistance to all
approved medicaments. Therefore new active compounds with different mode of action,
simple dosage and lower toxicity are still needed. To achieve that goal we have to under-
stand all the steps the virus takes during its life cycle in order to reproduce.
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1.1 HIV-1 Life Cycle
The HIV-1 replication cycle (Figure 1.1) is a multistep process regulated by viral and
cellular proteins, that lasts for 1.2 days and generates up to 1010 virions daily [8]. The
process starts when viral surface glycoprotein gp120 binds to chemokine receptors of the
human CD4+ cells and interacts with its coreceptors, CXCR4 and CCR5 [9]. This induces
conformational changes in gp120 subunit and transmembrane protein gp41 [10], which
result in a membrane fusion reaction. The viral core, that consists of capsid (CA) and
nucleocapsid proteins (NC), genomic RNA and three viral enzymes: HIV-1 proteinase
(PR), integrase (IN) and reverse transcriptase (RT), is released into the cell cytoplasm
[11].
Figure 1.1: The replication cycle of HIV-1. Adopted from [12].
After the fusion, RNA is uncoated in several steps that are not complementely under-
stood. Some of the structural proteins (matrix - MA and NC), enzymes (IN, RT) and
accessory protein Vpr are associated with a reverse transcription complex (RTC), that
generates the double stranded DNA from viral ssRNA. CA is completely degraded [13].
Later on, the preintegration complex (PIC) harbouring viral DNA is formed. PIC inter-
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acts with nucleoporins in the nuclear envelope and is transported into the host nucleus by
yet unknown mechanism [14]. The viral integrase incorporates viral DNA into the host
chromosome. The integrated viral DNA is called the provirus [11] and serves as a template
to create new viral RNAs that encode nine genes for successful virus replication (gag, pol,
env, nef, rev, tat, vif, vpr and vpu).
The assembly process takes place at the plasma membrane of the cell. The Gag
polyprotein binds to the membrane by myristic acid moiety and recruits two copies of
ssRNA. The assembled Gag polyprotein mediates Gag-Gag interactions and the formation
of budding particle. The Gag specific sequence refered to as ”L” or ”late” domain located
in p6 in Gag promotes the release of the immature virion from the cell. The mechanisms of
the release stimulation is not yet elucidated [15, 16]. Immediately after or during budding,
the viral PR cleaves Gag and GagPol polyproteins. It leads to viral maturation, during
which the rearrangement of the particle and core condensation occurs. Thus the virion
becomes infectious.
1.2 HIV-1 Genome and Protein Architecture
HIV virion contains diploid genome (Figure 1.2 on page 14) - 2 molecules of ssRNA (9 kb),
replicated by reverse transcriptase (RT). RNA encodes 9 genes, that are overlapping and
which are synthesized in a form of three main polypeptides : Gag, GagPol and Env. They
have to be proteolytically cleaved by viral or bacterial proteinase to become functional.
The Gag polypeptide is cleaved to structural proteins of the virion, pol codes viral enzymes
and env codes glycoproteins of the virion envelope that help to infect the target cell.
Translation of the gagpol gene leads to the proteosynthesis of either Gag (p55) or
GagPol (p160) polyproteins. In majority of cases the translation is terminated by the
stop-codon located in the p6 region of the gene which results in Gag production. How-
ever, in 5-10 % cases, a -1 ribosomal frameshift occurs that changes the open reading
frame and GagPol is synthesized [17]. The polyproteins are furthermore cotranslationally
myristoylated [18].
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Figure 1.2: The HIV-1 genome. ssRNA codes polyproteins Gag, Pol, Env. The gag gene
codes structural proteins (MA,CA, NC and p6), env gene codes envelope glycoproteins
(SU and TM) and pol gene encodes viral enzymes PR, RT and IN. Adopted from [11].
Gag polyprotein
Gag polyprotein is a precursor of several structural proteins of HIV similarly to other
retroviruses such as Rous sarcoma virus, Moloney murine leukemia virus and Mason-
Pfizer monkey virus [19]. Gag is processed by HIV-1 proteinase and the products of the
Gag cleavage are: matrix protein (MA - p17), capsid protein (CA - p24), nucleocapsid
protein (NC - p7), p6 peptide and two spacer peptides (p2 and p1) (Figure 1.3).
Figure 1.3: Structure of Gag polyprotein with pointed cleavage sites by HIV-1 proteinase.
Adopted from [20] and modified.
Matrix protein consists of five α-helices, a short three-β-stranded sheet [21] and the
myristic acid moiety attached to N-terminal Gly-residue. It targets Gag to plasma mem-
brane by exposing its myristate moiety to cell membrane. Specific deletion within MA
domain leads to disrupted targeting of HIV assembly [22]. Other studies indicate that MA
also plays role in Env incorporation to virion during virus budding [23, 24]. In mature
virion MA remains associated as a matrix layer within the inner viral membrane.
Capsid consists of two helical folded domains (N-terminal domain - NTD and C-terminal
domain - CTD) that are linked by a short linker [25]. CTD contains the major homology
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region of Gag which residues stabilize the conformation of the whole domain and thus
contributes to Gag-Gag interactions [25, 26]. NTD contains the Cyclophilin A binding
site, that packages the prolyl isomerase CypA from the host cell into the virion during
virus budding. Preventing CypA incorporation results in disturbed HIV infectivity. It
is suggested, that cypA might have function as a chaperone to prevent CA aggregation
during maturation [27, 28]. In mature particle, capsid creates the viral core that surrounds
HIV genome.
Nucleocapsid contains two zinc-finger motifs Cys-X2-Cys-X4-His-X4-Cys that coordin-
ate zinc ions [29]. These domains participate in RNA binding and encapsidation. NC
recognizes a packaging site (ψ site) on the RNA genome and RNA major groove interacts
with NC basic residues at positions 3 and 10 [20]. After maturation, nucleocapsid coats
the genomic RNA in the viral core [30].
Peptid p6 is a small Pro-rich protein, located at Gag C-terminus. It contains a highly
conserved Pro-Thr-Ala-Pro-Pro (PTAP) motif in its L domain, which inactivation leads
to impair virion release [31, 32]. The spacer protein p2 controls the viral maturation [33],
alteration in its first residues destroys proper viral assembly [34]. The function of p1 is
not yet understood [35].
GagPol polyprotein
GagPol polyprotein encodes besides structural proteins (MA, CA, p2, NC) also the trans-
frame protein (TFP) and three enzymes - reverse transcriptase (RT - p66/p51), integrase
(IN - p31) and proteinase (PR - p11).
RT is composed of two subunits p66 and p51 that overlap in protein sequence. Domain
p66 is derived from GagPol precursor, and after PR cleavage of 15 kDa RNaseH domain,
p51 is formed. Although the first residues of amino acid sequence of both subunits are
identical, they differ in structural composition. The active site and DNA-binding groove
is located in p66, p51 has the structural role [36]. The main role of RT is to transcribe
DNA from viral RNA [37]
The IN consists of N-terminal domain with zinc-finger, a central sequence and C-terminal
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domain. The active site (Asp64, Asp116 and Glu152) is situated in the central sequence.
IN acts as a multimer [38], and incorporates DNA into the host cell genome [39].
HIV-1 PR, which cleaves the Gag and GagPol polyproteins to mature viral components,
is discussed in detail in chapter 1.5.
The role of TFP is not clear yet, however, it is the most variable region and the
mutations of the viral genome in its gene do influence viral replication and infectivity [40].
Env polyprotein
The polypeptide Env codes the inactive precursor gp160 that is cleaved at the C-terminus
of a Lys/Arg-X-Lys/Arg-Arg motif into two envelope proteins gp120 (surface protein - SU)
and gp41 (transmembrane protein - TM) [41]. Gp41 anchors Env complex in the viral
membrane. The gp120 is noncovalently associated with gp41, and is highly glycosylated
[42] which may increase its antigenicity against neutralizing antibodies [43].
Last but not least, HIV-1 encodes six auxiliary proteins Nef, Rev, Tat, Vif, Vpr and
Vpu [44]. Tat is the transcriptional transactivator protein that increase the RNA synthesis
from HIV-1 LTR. Rev facilitates the transport of viral RNAs from nucleus to cytoplasm.
The functions of Vif, Vpr, Vpu and Nef are not completely understood and their detailed
analysis are beyond the scope of this thesis [13].
1.3 HIV-1 Assembly and Virion Maturation
The mature viral particle arises through two assembly steps. At first, the cluster of
immature Gag is formed around the RNA genome. The Gag molecules are able to interact
with envelope polyprotein (Env), which are embedded in the plasma membrane. The
capsid in Gag is condensed and it stimulates the coating of lipid bilayer by Env. This
results in budding of the immature virion from the cell [45].
The immature virion (Figure 1.4 on page 17) is a spherical particle with a ranging
diameter from 120-260 nm [46]. It consists of a layer of approximately 5000 Gag molecules
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associated radially to the inner plasma membrane [47]. Gag precursor is connected to the
cell membrane through myristic acid moiety that is joined to N-terminal Gly residue [48].
The C-terminal domain projects to the center of the particle. The Gag lattice is usually
open during virus budding and is stabilized by the cell membrane [33].
During the second step, the HIV-1 PR is autoactivated and cleaves Gag and GagPol
polyprotein precursors into mature proteins. The autoprocessing is not completely under-
stood, however, one theory claims that it is initiated by dimerization of two HIV-1 PR
domains embedded in GagPol precursor [49]. Gag cleavage leads to structural rearrange-
ments and to maturation of the virion.
In the middle of the mature and infectious viral particle (Figure 1.4) there is a capsid
core with a conical shape. It includes nucleocapsid protein, two molecules of genomic RNA
and viral enzymes (reverse transcriptase and integrase). The core is surrounded by lipid
bilayer with Env proteins - embedded gp41 and attached gp120. The inner site is covered
by MA layer. It is believed that HIV-1 PR is located in the matrix [11, 50].
Figure 1.4: The structure of mature and immature HIV particle. Adopted from [47] and
modified.
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1.4 Current HIV therapy
In 1996, the highly active antiretroviral therapy (HAART) was introduced into clinical
practice. It is a combination of 3-4 inhibitors that target viral enzymes. This type of
regime helps to slow down the development of the resistance to a specific compound and
provides synergism between different drugs, lowering their dosage and side effects. Due
to HAART the replication of the virus is suppressed for years, and the quality of people’s
lives increases [51].
Up to now, the U.S. Food and Drug Administration (FDA) has approved 36 antiretro-
viral drugs [52]. They may be divided into six categories according to their target in the
viral life cycle. For a review, see [51].
The cell entry inhibitors (enfuvirtide, maraviroc) or so called fusion inhibitors in-
teract with receptor proteins on the surface of the cell - the primary receptor CD4+ or
coreceptors CCR5 and CXCR4 [53]. The virus is thus unable to bind to the cell mem-
brane and gain entry into the host cell. Nucleoside Reverse Trascriptase Inhibitors
(abacavir, azidothymidine, didanosine, emtricitabine, lamivudine, stavudine, zalcitabine
and zidovudine) are analogues of 2’,3’-dideoxynucleoside (ddN). In the cell, they are phos-
phorylated by three steps into ddNTP and interact with the active site of RT. As a result,
they prevent synthesis of DNA and HIV replication. Nucleotide reverse transcriptase
inhibitors (tenofovir) have the similar effect on the catalytic centre of RT as nucleoside
inhibitors. The only difference is in their phosphorylation. Non-Nucleoside Reverse
Transcriptase Inhibitors (delavirdine, efavirenz, etravirine, nevirapine) are polycyclic
compounds that bind to an allosteric site of RT near the active site [54]. The integrase
inhibitor (Raltegravir) targets the catalytic function of the integrase enzyme, the integ-
ration of DNA strand into the host genome [55]. Proteinase inhibitors (discussed in




HIV-1 proteinase (EC 3.4.23.16, 11 kDa) belongs to the family of aspartic proteinases and
plays an important role in the late phase of HIV-1 life cycle. It cleaves Gag and GagPol
polyproteins at nine sites into structural proteins and enzymes. During this maturation
process, the uninfectious viral particle becomes fully infectious.
1.5.1 Structure of HIV-1 Proteinase
HIV-1 proteinase is active as a homodimer consisting of two identical subunits of 99
amino acids [57]. The 3D structure (Figure 1.5) was described by multiple studies using
crystallographic, NMR and computational analyses [57, 58, 59].
The active site possesses typical catalytic triad of Asp25-Thr26-Gly27 and is formed
by catalytic Asp25 of the both subunits at the bottom of the substrate-binding cleft. It is
stabilized by hydrogen bonds, between Thr26, Gly27 and catalytic aspartates, that form
a network called the fireman’s grip. The highly conserved N-terminal residues (1-5) and
C-terminal residues (95-99) contribute to dimerization of the enzyme [60]. The structure
contains also two β-hairpin loops known as flaps (residues 42-58 and 42’-58’). They are
very flexible and allow binding of the substrate or inhibitor to the active site. The flap
motion occurs in millisecond–microsecond timescale [61]. The most stable conformation
for the enzyme is semi-open [62].
Figure 1.5: The comparison of open and semiopen conformation of HIV-1 proteinase. Flap
regions are colored in yellow and purple. Adopted from [62] and modified.
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1.5.2 Specificity of HIV-1 Proteinase
HIV-1 proteinase cleaves Gag and GagPol polyproteins at 9 specific sites (Table 1.1).
HIV-1 PR identifies amino acids of the substrate in the P4 to P3’ position, whose side
chains interacts with HIV-1 PR subsites, marked as S4 to S3’ (Figure 1.6) [63]. The
shortest substrate is thus 7 amino acids long [64]. There is a preference for two types
of processing site - between aromatic amino acid and Pro, or between two hydrophobic
amino acids excluding Pro [65]. In type 1, the P2 residue is typically Asn, and P2’ is
Val/Ile, while in type 2 Glu/Gln is in P2’ position [63, 66].
Table 1.1: The sequences of HIV-1 PR cleavage sites. The cleavage occurs between P1
and P1’ residues. Adpted from [67].
P5 P4 P3 P2 P1 P1’ P2’ P3’ P4’ P5’
MA↓CA V S Q N Y P I V Q N
CA↓p2 K A R V L A E A M S
p2↓NC P A T I M M Q R G N
NC↓p1 E R Q A N F L G K I
p1↓p6 R P G N F L Q S R P
TF↓PR V S F N F P Q I T L
PR↓RT C T L N F P I S P I
RT↓RH G A E T F Y V D G A
RT↓IN I R K I L F L D G I
(a) (b)
Figure 1.6: (a) A schematic diagram of the MA↓CA cleavage site. Adopted from [63].




The cleavage of the Gag polyprotein is a highly regulated sequential process [50]. It
happens in a particular order and rate (Figure 1.7). The kinetic parameters for each
type of cleavage site are shown in Table 1.2.
Table 1.2: The kinetic parameters for the wild-type cleavage sites determined via hydro-
lysis of the respective oligopeptides by the wild-type HIV-1 proteinase. The values were
taken from [64, 69] and measured by the same method.
substrate sequence Km (mM) kcat (s
−1) kcat/Km (mM
−1s−1)
MA↓CA VSQNY↓PIVQN 0.15 6.9 46.0
CA↓p2 KARVL↓AEAMS 0.01 0.9 90.0
p2↓NC PATIM↓MQRGN 0.05 3.7 74.0
NC↓p1 ERQAN↓FLGKI 0.17 0.15 0.9
p1↓p6 RPGNF↓LQSRP 1.20 0.98 0.8
Gag cleavage kinetics was clarified by cell-free expression system of full-length Gag
polyprotein [70, 71]. At first, the processing occurs at p2↓NC and it forms two inter-
mediates MA-CA-p2 (41 kDa) and NC-p1-p6 (15 kDa). Then both of the products are
cleaved simultaneously at MA↓CA and p1↓p6. The rate is 10-fold lower than the first
cleavage. Finally, the spacer peptides p1 and p2 are disconnected from C-termini of NC
and CA. These reactions are several hundred-fold slower than the first one and thus they
are rate limiting [70]. In particular, the p1↓p6 is 9x slower, MA↓CA 14x slower, NC↓p1
350x slower and CA↓p2 400x slower than the cleavage of p2↓NC [70].
Figure 1.7: Proteolytic processing of Gag polyprotein by HIV-1 PR. The red arrows
indicate cleavage sites.
21
1.5.4 HIV-1 Proteinase Inhibitors
Proteinase inhibitors (PI) (Figure 1.8 on page 23) used in HIV therapy are tight binding
competitive inhibitors that were designed due to detailed knowledge of HIV-1 PR and its
specificity. The first generation of PIs are peptidomimetics of the scissile bonds in Gag
polyprotein [56]. Unfortunately, they are accompanied with numerous side effects, fast
resistance development and low bioavailability. Therefore, the second generation of PIs
were developed to overcome these problems. They were designed to inhibit HIV strains
resistant to drugs of the first generation. The compounds are much more efficient with
improved bioavailability and lowered toxicity and side effects [72, 73].
The first proteinase inhibitor approved by FDA was saquinavir (Ro-31-8959, Invirase R©)
in December 1995 [74]. It was based on specificity of HIV-1 PR to cleave the peptide
bond in sequence Asn,Phe↓Pro, which was substituted by a hydroxyethylamine isoester
[75]. In 1996, FDA approved another inhibitor called ritonavir (ABT-538, Norvir R©) [76].
Although, it was developed as C-2 symmetric molecule, it loses symmetry after being
bound into the PR active site. More importantly, it is an inhibitor of cytochrome P-450,
which is nowadays used in coadministration with other PIs [77]. Indinavir (MK-639,
L735.524, Crixivan R©) was developed on the base of resin inhibitors [78], and approved in
1996. Nelfinavir (AG-1343, Viracept R©) was licensed in 1997 as the first non-peptidic
competitive inhibitor and the first drug approved for children therapy [79].
The scaffold of saquinavir was used to develop the inhibitor amprenavir (VX-498,
141W94, Agenerase R©) [80], which was approved in 1999. It contains tetrahydrofurancar-
bamate and sulfonamide moieties. Fosamprenavir (VX-175, GW433908, Lexiva R©) is a
phosphate ester of amprenavir [81], approved in 2003.
In 2000, FDA approved the first inhibitor of the second generation, lopinavir (ABT-
378, Kaletra R©). Its combination with boosting agent ritonavir is used. Atazanavir
(BMS-232632, CGP 73547, Reyataz R©), licensed in 2003, is based on azapeptide analogues
[82]. The compound is an once-daily drug with low side effects and good tolerability.
The second nonpeptidomimetic inhibitor is tipranavir (PNU-140690, Aptivus R©) [83],
licensed in 2005. Its central scaffold is a dihydropyrone ring unlike a hydroxyethylene core
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in peptidomimetic PIs. Although tipranavir has efficacy against several drug resistant
strains, it has low tolerability and it is hepatotoxic [84]. It is also CYP450 3A4 inducer,
and therefore the therapy requires higher dose of ritonavir. The most recent approved
inhibitor (2006) is darunavir (TMC-114, UIC-94017, Prezista R©). The structure is derived
from amprenavir, with replaced tetrahydrofuranyl moiety by bis-tetrahydrofuranyl group
[85]. It improves hydrogen bonding and thus its effectivity.




The new approach to successfully inhibit the viral maturation, is to employ Gag polypro-
tein and target its cleavage sites [86]. The disruption of the regulated Gag processing leads
to reduced HIV-1 proteinase activity [87]. These specific inhibitors are called maturation
inhibitors and represent promising new types of antiretroviral drugs [88].
The prototype of maturation inhibitors is bevirimat (PA-457) (3-O-(3’3’- dimethyl-
succinyl)betulinic acid - Figure 1.9). It is a derivative of betulinic acid, a natural product
of plants, which is a weak inhibitor of HIV-1 replication [89]. The derivatization helps to
increase the activity of HIV-1 proteinase 1000-fold [90].
Figure 1.9: The chemical structure of bevirimat. Adopted from [91].
During the virus budding, bevirimat incorporates into HIV virion and associates with
the Gag protein in 1:1 stoichiometry [92]. It specifically binds to the cleavage site of CA↓p2
Gag polyprotein and inhibits thus the final rate-limiting step of Gag processing [93, 94].
The major determinants of bevirimat activity are the amino acid residues in N-terminal
part of peptide p2 [95]. Bevirimat also has a stabilizing effect on the immature capsid
lattice and blocks the conformational transformation of capsid [96]. The disruption of Gag
processing and stabilization of capsid results in the formation of abnormal virions with
an acentric core and the layer of Gag molecules nearby the plasma membrane [97]. These
HIV virus particles remain non-infectious.
Bevirimat is the first maturation inhibitor that has entered the clinical trials [98]. It
has an in vitro activity against both the wild-type and drug resistant HIV strains, with
IC50 value around 10 nM [97, 99]. However, mutations conferring to the resistance have
already emerged. Bevirimat has high specificity for HIV-1, with no activity against related
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retroviruses (HIV-2 and simian immunodeficiency virus) [100].
Other experimental inhibitor in clinical tests is vivecon (MPC-9055), which binds
within the CA↓p2 junction in Gag and therefore disturbs the proper Gag cleavage [101].
The chemical analogue of bevirimat is a compound called PA1050040, that should rep-
resent the second generation of HIV maturation drugs. A third generation inhibitor
UK-201844, that target gp160 processing in order to create non-functional Env proteins,
is in development [102, 103].
1.5.5 Resistance Development
Although HIV therapy is very effective, the resistance develops to all of the proteinase in-
hibitors and their combination. The drug-resistant viral species are emerging very quickly,
mainly under the selection pressure of PIs. It leads to the rapid viral replication and poten-
tial dual infections. The viral reverse transcriptase lacks its proofreading activity, which
causes the high mutation rate [56]. The pattern of mutations is very complex, and up to
49 positions in PR amino acid sequence are able to mutate [104]. The resistant mutations
within the PR effect the drug susceptibility.
Mutations in HIV-1 Proteinase
The amino acid changes leading to PI resistance (Figure 1.10 on page 26) are divided
into two groups depending on their effect. The major mutations are selected early
after initiation of the viral therapy, and they are specific to particular inhibitor. Most of
them are located in the proximity of the active site of the PR. They frequently affect the
processing of the Gag and GagPol polyproteins by enlargement of the catalytic centre of
the PR, which leads to weaker interactions between PI and the PR [105].
Later on, the minor mutations are selected to improve the viral fitness [105]. They
are located outside the substrate-binding cleft.
Although each PI selects different major mutations (Table 1.3 on page 26), they do
overlap and the mutant HIV strain is usually resistant to more than one PI, which is
known as cross resistance.
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Table 1.3: Positions of resistance mutations in HIV-1 proteinase. Data taken from [106].
PI Major mutations Minor Mutations
Amprenavir / 50, 84 10, 32, 46, 47, 54, 73, 76, 82, 90
Fosamprenavir
Atazanavir 50, 84, 88 10, 16, 20, 24, 32, 33, 34, 36, 46, 48, 53,
54, 60, 62, 64, 71, 73, 82, 85, 90, 93
Darunavir 47, 50, 54, 76, 84 11, 32, 33, 74, 89
Indinavir 46, 82, 84 10, 20, 24, 32, 36, 54, 71, 73, 76, 77, 90
Lopinavir 32, 47, 76, 82 10, 20, 24, 33, 46, 50, 53, 54, 63, 71, 73,
84, 90
Nelfinavir 30, 90 10, 36, 46, 71, 77, 82, 84, 88
Saquinavir 48, 90 10, 24, 54, 62, 71, 73, 77, 82, 84
Tipranavir 47, 58, 74, 82, 83, 84 10, 33, 36, 43, 46, 54, 69, 89
Figure 1.10: 3D structure of HIV-1 proteinase in complex with darunavir. The mutations
are shown in one monomer of HIV-1 PR. The major ones are colored in blue, minor in red
and polymorphic in yellow. Adopted from [107].
In 0.1 % of patients, amino acid insertions are selected in the lateral edge of the binding
cleft [108]. They have been observed ranging from 3 to 18 nucleotides, in PR coding regions
near positions 18, 25, 36, 70 and 95 [108]. These inserts are likely created by stalling and
slippage of reverse transcriptase. The insertions decrease PI susceptibility, improve viral
fitness [109] and contribute to HIV resistance development [110].
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Mutations in the Substrate
The mutations within Gag in cleavage sites have been observed both in vivo and in vitro
[111, 112]. These PI resistant variants display improved replicative capacity of the virus.
The mutations in cleavage sites (Table 1.4) are most often in the p2↓NC, followed
by p1↓p6, NC↓p1, CA↓p2 and MA↓CA [113]. The most frequently selected in vivo and
in vitro mutations are located in amino acid positions 128, 431, 436, 437, 449, 452 and
453. The mutant substrates show higher binding affinity and improved Gag processing
by mutant HIV-1 PR. This probably induces the shift in equilibrium of the complex -
Gag substrate / proteinase inhibitor with the HIV-1 PR towards the Gag substrate and
therefore causes resistance [114].
Table 1.4: Mutations in cleavage sites. Adopted from [114].
Cleavage site
MA↓CA V S Q N Y P I V Q N
position 128 129 130 131 132 133 134 135 136 137
variability (%) 3.5 - 4.3 - 3.5 - - 0.9 0.9 -
substitution I/T/A/del - - - F - - - - -
CA↓p2 K A R V L A E A M A
position 359 360 361 362 363 364 365 366 367 368
variability (%) 0.2 0.2 1.8 11.5 1.2 - - - - 1.2
substitution - V - I M/F/C/Y - - - - -
p2↓NC S A T I M M Q R G N
position 373 374 375 376 377 378 379 380 381 382
variability (%) 36.3 32.6 42.7 23.6 1.8 5.5 - 40.9 5.5 2.1
substitution P/Q/T P/S N/S V F - - - S -
NC↓p1 E R Q A N F L G K I
position 428 429 430 431 432 433 434 435 436 437
variability (%) 2.3 3.5 - 0.5 - - 0.1 - 6.3 5.5
substitution G - R V - - - - E/R T/V
p1↓p6 R P G N F L Q S R P
position 444 445 446 447 448 449 450 451 452 453
variability (%) - 0.1 - - - 9.1 - 22.8 - 8.4
substitution - - - - - F/P/V - T/G/R S/K A/L/T
The mutations were also identified in non-cleavage sites during PI therapy (Table 1.5
on page 28). The mechanism of their mediated resistance is, however, not clear. Several of
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the amino acid substitutions (L75R, H219Q, V390A/D, R409K and E468K) are resistant
to PIs in the presence of PR mutations. [115]. Other (R76K, Y79F, and T81A) reduce PI
susceptibility in the absence of PR mutations [116].
Table 1.5: Positions of mutations in Gag precursor protein outside of the cleavage sites.
Adopted from [114].
Gag polyprotein in vivo in vitro
MA 76, 79, 81 12, 62, 75, 112
CA - 200, 219
p2 369, 370, 371 -
NC 389, 401 390, 409
p6 474, 487, 497 468
Although the maturation inhibitor bevirimat is still in clinical studies, several muta-
tions have been identified to confer resistance. They are located at positions 358, 362,
363, 364, 366, 368 and 370 near the CA↓p2 cleavage site [103, 117].
The appearance of mutations in the Gag polyprotein and the possibility to target
the cleavage sites suggested to study Gag processing in more detail. Usually the kinetic
data were determined using oligopeptides. To obtain proper kinetic characteristic the
full-length Gag polyprotein is needed. To determine differences in Gag processing by the
wild-type and the mutant variants of HIV-1 PR and to assess the influence of mutations
in Gag cleavage sites to HIV resistance are the main goals of this thesis.
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Chapter 2
Aims of the Project
The main objective of this thesis was to study Gag processing.
It includes :
• to prepare the full-length recombinant Gag polyprotein
• to determine differences in Gag processing by the wild-type and by highly mutated
HIV-1 proteinase




3.1 List of Chemicals
Table 3.1: Used chemicals
Chemical Company Country
2-Mercaptoethanol Sigma-Aldrich USA
Acetic acid Penta Czech Republic
Acrylamid USB USA
Agarose Bio-Rad USA
Ammonium persulfate (APS) Sigma-Aldrich USA
Ampicillin (AMP) Biotika Slovak Republic
Bromphenol Blue Serva Germany
Bovine Serum Albumin (BSA) New England Biolabs UK
Coommassie Brilliant Blue G250 Serva Germany
DMSO Sigma-Aldrich USA
Ethanol Lach-Ner Czech Republic
Ethylenediaminetetraacetic acid (EDTA) Sigma-Aldrich USA
Formaldehyde Lachema Czech Republic
Glycin USB USA
Continued on next page
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Table 3.1 – continued from previous page
Chemical Company Country
Glycerol Penta Czech Republic
Imidazole Sigma-Aldrich USA
Isopropyl-β-D-thiogalaktopyranosid (IPTG) Biosynth Agm Switzerland
LB - agar Sigma-Aldrich USA
LB - medium Sigma-Aldrich USA
Methanol Penta Czech Republic
Nickel Sulfate Sigma-Aldrich USA
Phosphoric Acid Lachema Czech Republic
Sodium Acetate Penta Czech Republic
Sodium Carbonate (Na2CO3) Penta Czech Republic
Sodium thiosulphate, pentahydrate (Na2S2O3.5 H2O) Penta Czech Republic
N,N’-methylenbisacrylamide USB USA
Silver Nitrate (AgNO3) LachNer Czech Republic
Sodium Chloride (NaCl) Penta Czech Republic
Sodium Dodecyl Sulfate (SDS) Sigma-Aldrich USA
Sodium Sulfite Lachema Czech Republic
Sucrose Fluka Germany
Tetramethylethylenediamine (TEMED) Fluka Germany
Tris(hydroxymethyl)aminoethan (TRIS) Promega USA
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3.2 Instruments
Autoclave - MLS-3020 U, Sanyo (Japan)
Blotting - Trans - Blot SD Semi-Dry Electrophoresis Transfer Cell, BioRad (USA)
CCD Camera - LAS 3000, Fujifilm Corporation (Japan)
Centrifuges - Allegra X-15 R (Beckman Coulter), Avanti J-30 I (Beckman Coulter)
- Beckman J2-MI, Beckman Coulter (USA)
- Eppendorf centrifuge 5415R, Eppendorf (Germany)
Chromatography - AKTA explorer, Amersham Pharmacia Biotech (Sweden)
Electrophoresis - Horizontal electrophoresis apparatus, Shelton Scientific (USA)
- Vertical polyacrylamid electrophoresis, Amersham Pharmacia Biotech (Sweden)
Emulsiflex - Emulsiflex C-3 microfluidizer, Avestin (Germany)
pH Meter - Unicam 9450, Unicam (UK)
Rotary Incubator - Innova 44, New Brunswich Scientific (Germany)
Shaker - KS 260 basic shaker, IKA (Germany)
Spectrophotometers - UV-VIS Spectrophotometer UNICAM UV 500, Unicam (UK)
- UV- VIS Spectrophotometer SPECORD 210, Analytik Jena (Germany)
Transilluminators - UV Transilluminator, UltraLum (USA)
- Safe Imager Blue Light Transilluminator, Invitrogen (The Netherlands)
Thermal Cycler - Techne Progene Thermocycler (UK)
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3.3 Other Used Materials
Bacterial strains and vectors - E.coli DH5α, E.coli BL21(DE3)RIL, Novagen (USA)
- pET22b (AMP+), Novagen (USA)
Blotting - anti-capsid antibody (monoclonal, rabbit, lab of Hans-Georg Kräusslich)
- anti-matrix antibody (monoclonal, rabbit, lab of Jan Weber)
- PVDF membrane, Millipore (USA)
- SuperSignal West Femto Chemiluminescent Substrate, Pierce (USA)
Columns - Superdex 200 GL, GE Healthcare (UK)
- HiTrapTM Chelating HP columns, GE Healthcare (UK)
Enzymes - Phusion DNA Polymerase, T4 DNA Ligase, New England Biolabs (UK)
- restriction endonuclease : XhoI, Takara (Japan), NdeI, New England Biolabs (UK)
- drv6 HIV-1 proteinase (Prepared by Klára Grantz Šašková at IOCB AS CR)
- oligonucleotide primers, East Port (Czech Republic)
Filtration - Sterivex 0.22 µm Filter Unit, Millipore (USA)
Kits - Gel/PCR DNA fragments Extraction kit, Geneaid (Taiwan)
- High-Speed Plasmid Mini Kit, Geneaid (Taiwan)
Solutions - NEBuffer 4, T4 DNA buffer, GC buffer, New England Biolabs (UK)
- PPP Master Mix solution, TopBio (Czech Republic)
- Ethidium Bromide, Sigma-Aldrich (USA)
- SYBR Safe DNA gel stain, Invitrogen (The Netherlands)
Standards - MW standard - All Blue, BioRad (USA)
- 1 kb DNA ladder, New England Biolabs (UK)
Other materials - Darunavir, Tibotec, BVBA (USA)
- Chromogenous substrate KARVNIe↓NphEANIe-NH2 (Prepared by Mirka Blechova
at IOCB AS CR)




4.1 Cloning of Fusion Variants of Gag Polyprotein
The gene encoding the Gag polyprotein either with or without N-terminal poly-His-tag
was amplified by PCR reaction (Table 4.1A on page 35). The forward primers (Gag
fw, HisGag fw) containing the cleavage site for EcoRI (GAATTC) and NdeI (CATATG)
were specific to the 5’-end of the Gag coding region and the reverse primer (Gag rv) was
specific to 3’-end of the Gag coding region.
The MBP region (with and without C-terminal poly-His-tag) was amplified by PCR re-
action (Table 4.1B on page 35) using a forward primer (MBP fw) containing cleavage site
for TEV proteinase (GAAAACCTGTACTTCCAGTCT) specific to 3’-end of MBP coding
region and reverse primer (MBP rv, MBPHis rv) with cleavage site for XhoI (CTCGAG),
specific to 3’-end of the MBP coding region .
All the primers were synthesized by East Port (CZ) and used in concentration of 20 µM.
The PCR reactions were performed as follows:
1. 98 ◦C / 10 min
2. (98 ◦C / 30 s, 52 ◦C / 30 s, 72 ◦C / 180 s) 30 cycles
3. 72 ◦C / 8 min
The products were isolated from 1.2 % agarose gel (chapter 4.1.2) and fused together
in the second PCR reaction (Table 4.1C on page 35). The time of elongation step was
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Table 4.1: Sequence of PCR reactions used in preparation of DNA inserts.
product templates primers dNTPs PhuPol DMSO GC b. H2O
Gag-MBP A Gag (5 µl) 1, 2 (1 µl) 1 µl 0.5 µl 1.5 µl 10 µl 30 µl
B MBP (5 µl) 3, 4 (1 µl) 1 µl 0.5 µl 1.5 µl 10 µl 30 µl
C A, B (10 µl) - 1 µl 0.5 µl 1.5 µl 10 µl 17 µl
D C (1 µl) 1, 4 (1 µl) 1 µl 0.5 µl 1.5 µl 10 µl 34 µl
HisGag-MBP A Gag (5 µl) 5, 2 (1 µl) 1 µl 0.5 µl 1.5 µl 10 µl 30 µl
B MBP (5 µl) 3, 4 (1 µl) 1 µl 0.5 µl 1.5 µl 10 µl 30 µl
C A, B (10 µl) - 1 µl 0.5 µl 1.5 µl 10 µl 17 µl
D C (1 µl) 5, 4 (1 µl) 1 µl 0.5 µl 1.5 µl 10 µl 34 µl
Gag-MBPHis A Gag (5 µl) 1, 2 (1 µl) 1 µl 0.5 µl 1.5 µl 10 µl 30 µl
B MBP (5 µl) 3, 6 (1 µl) 1 µl 0.5 µl 1.5 µl 10 µl 30 µl
C A, B (10 µl) - 1 µl 0.5 µl 1.5 µl 10 µl 17 µl
D C (1 µl) 1, 6 (1 µl) 1 µl 0.5 µl 1.5 µl 10 µl 34 µl
Notes: Phusion Polymerase (PhuPol - 2000 U/ml)
Primer 1 (Gag fw) 5’-ATCGAATTCATATGGGTGCGAGAGCGTCG-3’
Primer 2 (Gag rv) 5’-AGACTGGAAGTACAGGTTTTCTTGTGACGAGGGGTCGCTGCC-3’
Primer 3 (MBP fw) 5’-GAAAACCTGTACTTCCAGTCTAAAATCGAAGAAGGCAAACTG-3’
Primer 4 (MBP rv) 5’-ACGGATCCTCGAGCTATTTGGTGATACGGGTCTG-3’
Primer 5 (HisGag fw) 5’-ATCGAATTCATATGCACCACCACCACCACCACGGTGCGAGAGCGTCGGTA3’
Primer 6 (MBPHis rv) 5’-ACGGATCCTCGAGTTTGGTGATACGGGTCTG-3’
extended from 180 s to 210 s. The products were amplified in the third PCR reaction
(Table 4.1D), in which the temperature of elongation step was 65 ◦C and time 210 s.
The purified PCR product was digested with two restriction endonucleases NdeI and
XhoI. The digestion reaction contained 10 µl of PCR product, 2 µl of NEB buffer 4, 2 µl
of BSA (10x), 0.5 µl of NdeI (20000 U/ml), 0.5 µl of XhoI (5000 U/µl) and 5 µl of sterile
H2O. The reaction mixture was left overnight at 37
◦C. Digested enzymes were denatured
at 65 ◦C for 20 min.
Isolated DNA was ligated into the expression vector pET22b. The reaction mixture
contained 10 µl of isolated DNA, 1 µl of plasmid, 2 µl of T4 DNA ligase buffer (10x),
0.5 µl of T4 DNA ligase (400000 U/ml) and 6.5 of sterile µl H2O. The ligation proceeded
4 h at laboratory temperature.
The ligation inserts were sequenced in DNA Sequencing Laboratory, Faculty of Science,
Charles University in Prague.
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4.1.1 Horizontal Agarose Gel Electrophoresis
TAE buffer (50x) - 2 M Tris, 1 M Acetic Acid, 50 mM EDTA, pH 8.0
Sample buffer - 40 % (w/v) sucrose, 0.1 % (w/v) bromphenol blue
DNA fragments were analyzed by horizontal agarose gel electrophoresis. To prepare
1.2 % gel, 0.72 g agarose was dissolved in 60 ml of TAE buffer (1x). The suspension was
heated in microwave oven until agarose melted and the evaporated water was refilled. After
cooling down, the fluorescent indicator ethidium bromide (60 µl of 0.5 mg/ml) was added
and the gel was poured into the casting platform and the comb was inserted. Solidified gel
was transferred to the electrophoresis apparatus filled with TAE buffer (1x). The DNA
samples mixed with the sample buffer were loaded to the gel and electrophoresis ran at
constant voltage of 110 V / 40 min. The ethidium bromide-stained DNA was visualized
using ultraviolet transilluminator. When DNA was isolated from the agarose gel, the 6 µl
SYBR safe DNA gel stain (10000x diluted) was added to gel solution instead of ethidium
bromide. This gel was visualized with blue light transilluminator.
4.1.2 DNA Isolation from Agarose Gel
DNA fragments were isolated using Geneaid Gel/PCR DNA fragments Extraction kit
according to the manufacturers instuctions. Gel slice (300 mg) with relevant DNA was
dissolved in 500 µl of DF buffer and the suspension was incubated at 60 ◦C for 10 min.
After cooling down, the sample was transferred to collection tube and centrifuged (14000 g,
30 s) in order to bind DNA to the membrane. It was washed with 400 µl of W1 buffer by
centrifugation (14000 g, 30 s) and with 600 µl of Wash buffer by centrifugation (140000 g,
30 s), and spinned down again to dry the column matrix. Dried column was transferred
into a new microtube, and 30 µl of Elution buffer was added to the center of the column
matrix. It was left for 2 minutes, and then the purified DNA was eluted by centrifugation
(14000 g, 2 min).
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4.1.3 Transformation of Bacterial Cells
To prepare agar plates, LB agar (8.75 g) was dissolved in water (250 ml) and sterilized at
121 ◦C for 15 minutes by autoclave. Ampicillin was added to the final concentration of
0.1 mg/ml and 10 ml of this solution was poured on the sterile Petri plate.
The ligation product (20 µl) was added to 100 µl of competent cells Escherichia coli
DH5α. It was left 30 min on ice, 90 s in 42 ◦C (heat shock) and 120 s on ice. It was
followed by cell incubation with 300 µl of sterile medium at 37 ◦C for 1 h. The cells were
plated on the prepared agar plates and incubated overnight at 37 ◦C.
4.1.4 Isolation of the Plasmid DNA
Single colony grown on LB agar plates was picked and transferred into 5 ml of sterile LB
medium with ampicillin (1000x). The bacterial inoculum was incubated in rotary incub-
ator overnight at 37 ◦C, and the plasmid DNA was isolated from the cultured bacterial cells
using High-Speed Plasmid Mini Kit according to the manufacturers instructions. Grown
bacterial culture was centrifuged at 14000 g for 1 min and resuspended in 200 µl of PD1
buffer containing RNase A. 200 µl of PD2 buffer was added, gently mixed and left at room
temperature until the lysate was homogeneous. Lysate was neutralized by the addition
of 300 µl of PD3 buffer, stirred and centrifuged (14000 g, 3 min). The supernatant was
transferred into the PD column and centrifuged (14000 g, 30 s). The bound DNA was
washed with 400 µl of W1 buffer by centrifugation (14000 g, 30 s) and with 600 µl of
Wash buffer by centrifugation at the same conditions. The column matrix was dried by
centrifugation at 14000 g for 3 min and then 50 µl of Elution buffer was added into its
center. DNA was eluted by centrifugation (14000 g, 2 min).
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4.2 Protein Expression
Lysis buffer A - 50 mM Tris, 50 mM NaCl, 1 mM EDTA, pH 8.0
Competent cells E. coli BL21(DE3)RIL (50 µl) were transformed by the expression
vector coding the Gag polyprotein (2 µl). The transformation was carried out as in
chapter 4.1.3.
Freshly grown colonies on agar plates were resuspended in 12 ml of LB medium and
inoculated in 500 ml of sterile LB medium supplemented with AMP (100 µg/ml). They
were grown in a rotary incubator at 37 ◦C, 220 rpm. After reaching the OD595 value of
0.7, the expression was induced by addition of IPTG to final concentration of 0.75 mM.
The cells were incubated for 3 h at the same conditions and then centrifuged (20 000 g,
10 min, 25 ◦C). The pellet was weighed and resuspended in the lysis buffer A (10 ml of
buffer A per 1 g of wet biomass).
Only the product HisGag-MBP was used in the following experiments. The expression
conditions were the same, the production was, however, carried out in 6 x 500 ml of sterile
LB medium with AMP (100 µg/ml). After pelet resuspension in lysis buffer, one tablet of
the proteinase inhibitor cocktail (Roche) was added and it was frozen in -80 ◦C for later
use.
4.3 Protein Isolation and Purification
Thawed solution was three times homogenized using Potter homogenizer and then the cells
were lysed three times via Emulsiflex using homogenizing pressure set to 10000-15000 psi.
The lysate was centrifuged at 10000 g, 20 min, 4 ◦C and the supernatant was filtered
through a 0.22 µm syringe filter.
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4.3.1 Immobilized-metal Affinity Chromatography
Buffer A - 20 mM Tris, 0.1 % 2-mercaptoethanol, pH 8.0
Buffer B - 20 mM Tris, 0.1 % 2-mercaptoethanol, 500 mM imidazole, pH 8.0
To purify the His-tag protein the immobilized-metal affinity chromatography (IMAC)
was used. It is based on affinity of Ni2+ metal ion to histidine residues of the His tag. The
purification proceeded on 2 HiTrapTM Chelating HP columns (1 ml volume) attached to
the AKTA Explorer liquid chromatography system. The column was charged with 0.1 M
nickel sulfate.
During the protein purification, the flow rate was 1 ml/min. The column was equi-
librated with the buffer A and then the protein sample was loaded. It was subsequently
washed with buffer A and the bound proteins were eluted by a gradient of 0-5 % of buffer
B in 10 min and 5-100 % of buffer B in 20 min. The protein concentration in eluates
during the procedure was monitored by Bradford assay (chapter 4.4.1). Protein fractions
were analyzed by SDS electrophoresis (chapter 4.4.2).
4.3.2 Gel Permeation Chromatography
Buffer B - 20 mM Tris, 0.1 % 2-mercaptoethanol, 500 mM imidazole, pH 8.0
Gel permeation chromatography (GPC) was used to fractionate the protein based on
the size. The elution fractions from IMAC were loaded on the column Superdex 200 equi-
librated with buffer B. The flow rate was 0.4 ml/min and the purification was monitored
by on-line absorbance measurement at 280 nm. After protein separation, the peak frac-
tions were analyzed by SDS electrophoresis (chapter 4.4.2), and the protein concentration
was determined by Bradford analysis (chapter 4.4.1). The fractions containing purified
protein HisGag-MBP were pooled and stored at -80 ◦C.
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4.4 Protein Analysis
4.4.1 Determination of Protein Concentration
Commassie blue G-250 solution - 100 mg Commassie brilliant blue G-250, 50 ml 96 %
ethanol, 100 ml 85 % phosphoric acid, 850 ml sterile water
The protein concentration was determined using the Bradford method [118]. The
samples contained a range of 15 - 100 µl of protein, 200 µl of Coomassie Brilliant Blue
G-250 and sterile water was added to a total volume of 1 ml. The samples were incubated
for 5 min at laboratory temperature, the absorbance at 595 nm was analyzed and the
value of protein concentration was established from the calibration curve of Bovine serum
albumin (BSA).
4.4.2 SDS - Polyacrylamid Gel Electrophoresis
Sample buffer (6x) - 3.5 ml 1M Tris, 3 ml glycerol, 1 g SDS, 600 µl 2-mercaptoethanol,
1.2 mg bromphenol blue, water to 10 ml, pH 6.8
Electrode buffer - 25 mM Tris, 250 mM glycin, 0.1 % (w/v) SDS
44 % polyacrylamide solution (AAmix) - 42.8 g acrylamide, 1.2 g N,N’-methylenbisacrylamide,
water to 100 ml
The protein isolation and purification steps were monitored by discontinuous Sodium
Dodecyl Sulphate Polyacrylamide Gel Electrophoresis (SDS-PAGE). The samples were
separated using a 6.6 % stacking gel and 10 % or 18 % separating gel, prepared as described
in Table 4.2 on page 41.
The samples were mixed with the sample buffer in the ratio of 5:1 and they were
denatured by boiling for 5 min. The commercial standard All Blue was used to determine
molecular weight. Electrophoresis was carried out at constant voltage of 140 V, 1 h.
Separated proteins were stained by silver (Table 4.3 on page 41).
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Table 4.2: The preparation of polyacrylamide gels
separating gel (10 %) separating gel (18 %) stacking gel (6.6 %)
1.5 M Tris-HCl 2.5 ml 2.5 ml 1.25 ml
44 % AAmix 2.3 ml 4 ml 750 µl
10 % (w/v) SDS 100 µl 100 µl 50 µl
TEMED 10 µl 10 µl 10 µl
10 % APS 100 µl 50 µl 50 µl
sterile water to 10 ml 10 ml 5 ml
Table 4.3: Silver staining of proteins on SDS-PAGE
step solution time
1 12 % (v/v) acetic acid, 50 % (v/v) methanol, 30 min
0.02 % (v/v) formaldehyde
2 50 % (v/v) methanol 3 x 15 min
3 Na2S2O3.5 H2O (0.2 g/l) 1 min
4 sterile water 3 x 20 s
5 AgNO3 (2 g/l), 0.02 % (v/v) formaldehyde 20 min
6 sterile water 3x 20 s
7 Na2CO3 (60 g/l), Na2S2O3.5H2O (4 g/l), until bands appear
0.02 % (v/v) formaldehyde
8 sterile water 3 x 20 s
9 12 % (v/v) acetic acid, 50 % (v/v) methanol 10 min
10 10 % (v/v) acetic acid overnight
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4.4.3 Western Blotting
Blotting concentrate - 72.1 g glycine (1.92 M), 15.1 g Tris (250 mM), water to 500 ml
Blotting buffer - 10 ml blotting concentrate, 8 ml methanol, 1 ml 10 % (w/v) SDS, water
to 100 ml
Blocking buffer - 3 % Bovine Serum Albumin (BSA) (w/v) in PBS
The proteins separated by SDS electrophoresis gel were transferred to a polyvinylidene
difluoride (PVDF) membrane. The polyacrylamide gel, PVDF membrane and filter papers
were equilibrated in blotting buffer and placed on the transfer apparatus in the following
order (from anode to cathode) : 2x filter paper - PVDF membrane - polyacrylamide gel -
2x filter paper. The transfer was performed at constant voltage of 15 V for 15 min.
The membrane was blocked in 5 ml of blocking buffer for 1 h, and then incubated with
primary anti-capsid antibody (rabbit, 1:1000) overnight at 4 ◦C. Membrane was washed
three times by PBS + 0.05 % Tween-20 and then was complexed with secondary HRP-
conjugated antibody (anti-rabbit) for 1 h at 4 ◦C. The membrane was washed again by
PBS + 0.05 % Tween-20 and incubated with SuperSignal West Femto Chemiluminescent
Substrate. The chemiluminiscence signal was captured using CCD camera.
After developing the blot, the membrane was washed three times in PBS and then
incubated in 5 ml of stripping buffer (Pierce, USA) for 15 min. It was washed again,
and the primary anti-matrix antibody (rabbit, 1:3000) was added. The Western blotting
proceeded as before.
4.5 Kinetic Measurements
4.5.1 Determination of Kinetic Constants
Reaction buffer - 2 mM Tris, 50 mM imidazole, 500 mM sodium acetate, 0.01 % 2-mercaptoethanol,
pH 4.63
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The kinetic parameters were determined for the wild-type HIV-1 proteinase as well as
the mutated drv6 HIV-1 PR. This variant, that was selected as a representative mutant of
HIV-1 PR, contains amino acid exchanges L10I, I13V, I15V, K20R, L33F, E34N, E35D,
M36I, K43T, I47V, I50L, F53L, Q58E, I62V, L63P, I66F, A71V, V77I, V82A, I84V, L89V.
It was purified in our laboratory by Grantz Šašková et al. [119].
The spectrophotometric assay employed the chromogenic peptide substrate
KARVNIe↓NphEANIe-NH2 (Nle is norleucine, Nph is p-nitrophenyl-alanine), which was
derived from the cleavage site Ca↓p2 in Gag polypeptide. The decrease in absorbance at
305 nm caused by CA↓p2 cleavage was observed, and the shift in 1 ml of reaction mixture
at 37 ◦C in 1 cm cuvettes was monitored using an UV/VIS spectrophotometer.
Michaelis-Menten constant Km and the maximum rate Vmax were determined from
the measurement of initial rate (v0) of the substrate cleavage (15 µM) by the wild-type
proteinase (9 nM) and by increasing the substrate concentrations with constant PR con-





where v0 is the initial rate of the reaction, Vmax is the limit reaction rate, Km is Michaelis-
Menten constant and [S] is concentration of the substrate.
The catalytic efficiency kcat was determined by transforming all the substrate (10.5 µl,





V Amax ∗ [S0]
[E]0 ∗∆A
(4.2)
where VAmax is the maximum velocity expressed as the absorbance decrease per unit of time,
[E0] is the total enzyme concentration in the cuvette, [S0] is the enzyme concentration in
the reference experiment in which its total cleavage by PR was facilitated, and ∆A is the
corresponding change in absorbance.
The same principles were used to determine kinetic parameters for drv6 HIV-1 PR in
the same reaction buffer. The final concentration of drv6 in all reactions was 8.3 nM.
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4.5.2 Kinetics of Gag Processing
Stock buffer (10x) - 5 M Sodium Acetate, pH 4.4
The obtained protein HisGag-MBP was cleaved by either the wild-type HIV-1 pro-
teinase (10 nM) or mutated HIV-1 PR - variant drv6 (10 nM).
The substrate cleavage was performed in several reaction mixtures (Table 4.4). The
kinetics was observed in 24 hour interval. All the reactions proceeded at laboratory tem-
perature and they were stopped by adding 4 µl of Sample buffer from SDS-PAGE and
boiled in 100 ◦C water for 5 s. Two negative controls were used, one without HIV-1
PR and another with the addition of HIV-1 PR inhibitor darunavir (drv - 30 nM). The
Gag processing was analyzed by SDS-PAGE and Western blotting using anti-capsid and
anti-matrix antibodies.
The Gag processing was also observed by cleavage with mutated HIV-1 proteinase drv6,
that was used in the same concentration as the wild-type PR. The cleavage conditions
remained the same.
Table 4.4: The cleavage experiments
time S (200 nM) PR (10 nM ) H2O stock b. drv
SDS-PAGE samples 0,1,5,10,24 h 4 µl 0.8 µl 4.2 µl 1 µl -
control 1 24 h 4 µl - 5 µl 1 µl -
control 2 24 h 4 µl 0.8 µl 3.4 µl 1 µl 0.8 µl
Western samples 0,1,5,10,24 h 2 µl 0.4 µl 6.6 µl 1 µl -
blotting control 1 24 h 2 µl - 7 µl 1 µl -




5.1 Preparation of Individual DNA Constructs of Gag
Polyprotein
Three Gag variants designed within this diploma thesis are schematically shown in Figure
5.1. They were marked as Gag-MBP, HisGag-MBP and Gag-MBPHis according to N- or
C-terminal poly-His-tag and maltose binding protein (MBP).
Figure 5.1: Scheme of prepared Gag variants.
DNA sequence of the variant Gag-MBP is shown in Figure 5.2 on page 46. At first,
the Gag (MBP) sequence was amplified using Gag fw and Gag rv primers (MBP fw, MBP
rv) (Figure 5.3a on page 46). After DNA isolation, the target fragments (Gag - 1521 bp
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and MBP - 1110 bp) were joined in second PCR reaction and the yield of the fused product
was increased by the third round of PCR reactions (Figure 5.3b).
Figure 5.2: DNA sequence of Gag-MBP with pointed cleavage sites for restriction enzymes.
The sequence of primers are highlighted in blue (Gag fw, Gag rv) and green (MBP fw,
MBP rv).
The isolated final products were cleaved by restriction enzymes NdeI and XhoI and
ligated into the pET22b expression vector. E.coli DH5α cells were transformed by ligation
product (chapter 4.1.3) and the DNA minipreparations were carried out (chapter 4.1.4).
The successful ligation was confirmed by restriction cleavage on agarose gel electrophoresis
(Figure 5.4 on page 47). Sequence analysis of the inserts confirmed the correct clones.
(a) (b)
Figure 5.3: Agarose gel electrophoresis. (a) The gag and mbp genes amplified by PCR
reaction. Lane 1: 1kb DNA ladder, lane 2: gag (primers 1,2), lane 3: MBP (primers 3,4),
lane 4: HisGag (primers 5,2), lane 5: MBPHis (primers 3,6) (b) Fused products. Lane 1:
1kb DNA ladder, lane 2: Gag-MBP, lane 3: HisGag-MBP, lane 4: Gag-MBPHis. In both
gels, the irrelevant lanes were omitted for clarity.
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Figure 5.4: The agarose electrophoresis confirming the presence of the DNA fragment
encoding the GagMPB in plasmid pET22b. Lane 1: 1kb DNA ladder, lane 2: Gag-MBP,
lane 3: HisGag-MBP, lane 4: Gag-MBPHis. The irrelevant lanes on the gel were omitted.
5.2 Test of Recombinant Expression of Individual Gag
Variants
The competent cells E.coli BL21(DE3)RIL were transformed by all three protein variants.
The cultures were grown at 37 ◦C for 4 h in 0.5 l of LB media with ampicillin and the
recombinant expression was induced by adding IPTG to final concentration of 0.75 mM.
After 3 h of incubation, the cells were harvested and the pellet was weighted: 2.9 g of
wet biomass was pelleted by centrifugation of protein Gag-MBP, 2.9 g by HisGag-MBP
and 1.8 g by Gag-MBPHis per 0.5 liter of culture. The cells were resuspended in the lysis
buffer A and disrupted at 4 ◦C using emulsiflex. All of the fractions were analyzed on
18 % SDS-PAGE gel (Figure 5.5a on page 48).
5.3 Upscaled Recombinant Expression of HisGag-MBP
The E.coli BL21(DE3)RIL strain was transformed by the DNA coding the HisGag-MPB
variant, and the cells were grown in 6 x 0.5 l of LB media. The bacterial growth was
monitored by measuring OD595 as shown in Figure 5.6 on page 48. When OD595 reached
the value of 0.7, the expression was initiated by addition of IPTG to a final concentration of
0.75 mM. The cells were lysed and the collected fractions were analyzed on 18% SDS-PAGE
gel (Figure 5.5b on page 48). The cells overexpressing HisGag-MBP variant contained
a large amount of soluble protein, which was subsequently used for further purification.
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(a) (b)
Figure 5.5: (a) 18 % SDS-PAGE showing the expression of protein variants. Lanes 2-5:
Gag-MBP, lanes 6-9: HisGag-MBP and lanes 10-13: Gag-MBPHis, lane 1: MW standard,
lanes 2, 6, 10: bacterial cells before induction, lanes 3, 7, 11: bacterial cells after induction,
lanes 4, 8, 12: bacterial cells after cell lysis, lanes 5, 9, 13: supernatant after cell lysis.
(b) The upscaled expression of HisGag-MBP. Lane 1: 1kb DNA ladder, lane 2: bacterial
cells before induction, lane 3: bacterial cells after induction, lane 4: bacterial cells after
cell lysis, lane 5: supernatant after cell lysis.
Figure 5.6: The growth curve of E.coli BL21(DE3)RIL transformed with HisGag-MBP
expression vector. When OD595 reached the value of 0.7, the expression was induced by
0.75 mM IPTG.
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5.4 Purification of HisGag-MBP
Immobilized-metal affinity chromatography was employed for purification of His-tagged
protein HisGag-MBP. The column was precharged with Ni2+, equilibrated with buffer A
and the cell lysate was loaded on the column. The trapped protein was eluted by gradient
of 500 mM imidazole (chapter 4.3.1). The process of elution is seen in Figure 5.7. A
considerable portion of HisGag-MBP (lane 2) runs through the column without binding
(lane 3), and some of HisGag-MBP protein was washed away (lane 4). Bound HisGag-
MBP protein (97 kDa) was eluted in fractions 8-10 and in end-fraction containing 100 %
of buffer B (lane 10).
The eluted fractions (8, 9, 10 and 100 %) were collected, pooled and purified using
GPC chromatography in 3 portions due to limited column capacity (chapter 4.3.2). The
buffer contained 500 mM imidazole to stabilize the protein during purification. The eluted
fractions were analyzed on 10 % SDS gel (one of three rounds Figure 5.8 and Figure 5.9
on page 50). All the fraction containing HisGag-MBP were collected and the concentration
was analyzed (chapter 4.4.1). The final yield of the HisGag-MBP protein was 1 mg/l of
LB media. Total amount of the protein was 4 mg.
Figure 5.7: 18 % SDS PAGE gel showing protein purification using IMAC. Lane 1: MW
standard (1 µl), lane 2: load (3 µl), lane 3: flow through (3 µl), lane 4: wash 1 (3 µl),
lane 5: wash 2 (3 µl), lane 6: 0-5 % of buffer B (3 µl), lanes 7, 8, 9: 5-100 % of buffer B
(5 µl), lane 10: 100 % of buffer B (5 µl).
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Figure 5.8: 10 % SDS PAGE gel showing purity of HisGag-MBP in elution fractions
during gel permeation chromatography. Lane 1: MW standard (0.5 µl), lane 2: load
(5 µl), lanes 3-15: protein fractions (10 µl).
Figure 5.9: The chromatogram illustrating HisGag-MBP purification.
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5.5 Determination of Kinetic Constants
The HisGag-MBP (in the solution of 20 mM Tris and 500 mM imidazole, pH = 8.0) was
prepared as substrate for HIV-1 PR. The optimal conditions for HIV-1 PR activity is: 150
mM sodium acetate, 300 mM NaCl, 4 mM EDTA, pH 4.7. Therefore, the buffer (5 M
sodium acetate, pH 4.4) was used to decrease pH in the final reaction mixture and the
HisGag-MBP cleavage by HIV-1 PR was performed in the buffer with final pH 4.63 and
50 mM imidazole (chapter 4.5.1). The spectroscopic assay was performed to find out if
the PR is active also in such conditions.
All the measurements were performed using the chromogenic peptide substrate
KARVNIe↓NphEANIe-NH2. The kinetic parameters for the wild-type and mutant pro-
teinase (drv6) as well as the reference values in optimal conditions are summarized in
Table 5.1. The Michaelis-Menten constant (Km) and the turnover number (kcat) are
altered only slightly with respect to reference value. However, the efficiency of the sub-
strate’s cleavage of the wild-type PR (kcat/Km) decrease to the half and the efficiency of
mutant PR remains almost the same.
Table 5.1: The kinetic parameters for the wild-type and the mutant drv6 HIV-1 PR [119].
Km (µM) kcat (s
−1) kcat/Km (mM
−1s−1)
wild-type PR (optimal) 15 ± 1 30 ± 1.8 1990 ± 210
wild-type PR (final) 21 ± 0.7 20 ± 0.7 951.9 ± 12.9
mutant PR (optimal) 53 ± 2 9.6 ± 0.2 180 ± 7
mutant PR (final) 50.9 ± 5 8.9 ± 0.8 174.8 ± 2.8
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5.6 Gag Processing by the Wild-type HIV-1 Proteinase
To determine the HisGag-MBP polyprotein processing by both wild-type and mutant
HIV-1 PR, several reaction mixtures were prepared (chapter 4.5.2). The final volume of
each reaction was 10 µl, in which the ratio of the substrate to enzyme was 20:1. All the
cleavage reactions were performed at laboratory temperature and the process of cleavage
was captured at different time points. Two controls were used, one without the addition
of the PR (control 1) and one with the addition of the PR inhibitor darunavir (control 2).
The samples were analyzed by SDS-PAGE and Western blotting.
The kinetics of HisGag-MBP by the wild-type proteinase is shown in Figure 5.10. The
number of molecular mass of the bands were estimated according to expected molecular
weight of the proteins. At the start of the experiment (0 h) and in both of the controls,
the band of ∼97 kDa corresponding to the HisGag-MBP is clearly visible. After 1 h, the
bands of ∼41 kDa and ∼56 kDa appear, that may correspond to the first products of
PR cleavage MA-CA-p2 and NC-p1-p6-MBP. After 1 h, there are also visible bands of
∼48 kDa, ∼25 kDa, and ∼17 kDA, that may represent the structural proteins p6-MBP,
CA and MA, respectively. The intensity of the bands is increasing in time (5 h, 10 h and
24 h). In the last lane, the CA marker is used, which represents the CA protein itself.
Figure 5.10: 18 % SDS PAGE gel showing processing of HisGag-MBP by the wild-type
HIV-1 PR for different time periods Lane 1: MW standard (2 µl), lane 2: 0 h (14 µl),
lane 3: 1 h (14 µl), lane 4: 5 h (14 µl), lane 5: 10 h (14 µl), lane 6: 24 h (14 µl), lane 7:
control 1, 24 h (14 µl), lane 8: control 2, 24 h (14 µl), lane 9: CA marker (3 µl).
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To clarify the cleavage products, Western blotting procedure using anti-capsid (Fig-
ure 5.11a) and anti-matrix antibodies (Figure 5.11b) was performed. The anti-capsid
antibody recognizes the band of ∼97 kDa at 0 h and in both of the controls representing
the HisGag-MBP. With increasing time, the bands of ∼41 kDa and ∼25 kDa appear, that
correspond to the cleavage products CA-MA-p2 and CA. After 24 h, the band of ∼41 kDa
is not visible.
The anti-matrix antibody visualizes the band of ∼97 kDa, ∼41 kDa and ∼18 kDa at
the start of the experiment (0 h) and in both of the controls. These bands correspond to
HisGag-MBP, CA-MA-p2 and the impurity with MA sequence. The band of ∼41 kDA
decreases in time. After 1 h, the band of ∼17 kDa representing MA appears, and increase
in time (5, 10 and 24 h).
Both the antibodies are specific mainly to free CA/MA and therefore the full-length
HisGag-MBP protein is not very well visible on the blot.
(a) (b)
Figure 5.11: Stripped Western blotting membrane showing processing of HisGag-MBP by
the wild-type HIV-1 PR for different time periods (a) anti-capsid antibody (b) anti-matrix
antibody Lane 1: MW standard (3 µl), lane 2: 0 h (14 µl), lane 3: 1 h (14 µl), lane 4: 5 h
(14 µl), lane 5: 10 h (14 µl), lane 6: 24 h (14 µl), lane 7: control 1, 24 h (14 µl), lane 8:
control 2, 24 h (14 µl), lane 9: CA marker (3 µl).
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5.7 Gag Processing via Wild-type and Mutant HIV-1
Proteinase
To compare the Gag cleavage by the wild-type and mutant PRs, the same reactions as in
chapter 5.6 were performed analysing also the drv6 HIV-1 PR [119] which is resistant to
PI darunavir (Figure 5.12). At the start of the experiment (0 h) the band of ∼97 kDa
is observed in reactions with wild-type and mutant PR, and in both of the controls.
After 1 h, the bands of ∼56 kDa, ∼48 kDa and ∼41 kDa can be observed. The same
bands appear also after 24 h in reaction with mutant HIV-1 PR and inhibitor darunavir
(control 2). These bands correspond to the cleavage products NC-p1-p6-MBP, CA-MA-p2
and structural protein p6-MBP. After 5 h, in reactions with wild-type PR these bands
disappear and the bands of ∼25 kDa and ∼17 kDa representing CA and MA can be seen.
The amount of MA and CA increase over time (10 and 24 h). On the contrary, in reactions
with mutant PR is visible the band of ∼41 kDa that decrease over time and the bands of
∼25 kDa and ∼17 kDa increase over time more slowly.
Figure 5.12: 18 % SDS PAGE gel showing processing of HisGag-MBP by the wild-type
HIV-1 PR and drv6 for different time periods Lane 1: MW standard (2 µl), lanes 2, 4, 6,
8, 10, 12: wild-type PR, lanes 3, 5, 7, 9, 11, 13: drv6, lanes 2,3: 0 h (14 µl), lanes 4,5:
1 h (14 µl), lanes 6,7: 5 h (14 µl), lanes 8,9: 10 h (14 µl), lanes 10,11: 24 h (14 µl),
lanes 12,13: control 2, 24 h (14 µl), lane 14: control 1, 24 h (14 µl), lane 15: CA marker
(3 µl).
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The products with CA (MA) sequence were recognized via anti-capsid (anti-matrix)
antibody (Figure 5.13). The anti-capsid antibody visualized the band of ∼97 kDa after
0 h and in both of the controls corresponding to HisGag-MBP. The band of ∼41 kDa
representing CA-MA-p2 appears after 1 h, and slowly disappears in reactions with wild-
type PR. However, the band remains in reaction with mutant PR. This band can be seen
also in control 2 with inhibitor darunavir and mutant PR. After 1 h, the band of ∼25 kDa
representing CA is visible and slowly increases over time in reactions with wild-type PR.
After 24 h, this band appears also in reactions with mutant PR.
On the stripped blot using anti-matrix antibody the same bands of ∼97 kDa and
∼41 kDa can be observed that represent HisGag-MBP and CA-MA-p2. Furthermore, the
band of ∼18 kDa is visible at the start of the experiment, in both of the controls and in
reaction using mutant PR. The band of ∼17 kDa corresponding to MA appears after 1 h
of cleavage by the wild-type PR. After 5 h, the band can be seen also in reactions with
mutant PR.
(a) (b)
Figure 5.13: Stripped Western blotting membrane showing processing of HisGag-MBP by
the wild-type HIV-1 PR and drv6 for different time periods (a) anti-capsid antibody (b)
anti-matrix antibody Lane 1: MW standard (3 µl), lanes 2, 4, 6, 8, 10, 12: wild-type PR,
lanes 3, 5, 7, 9, 11, 13: drv6, lanes 2,3: 0 h (14 µl), lanes 4,5: 1 h (14 µl), lanes 6,7: 5
h (14 µl), lanes 8,9: 10 h (14 µl), lanes 10,11: 24 h (14 µl), lanes 12,13: control 2, 24 h




The regulation, order and rate of the Gag processing by HIV-1 proteinase has been in-
vestigated by several groups in order to design HIV-1 proteinase inhibitors.
In number of biochemical studies, short oligopeptides representing naturally occurring
cleavage sites were used to obtain individual kinetic parameters [64, 69]. However, these
data do not correspond with further work using full-length Gag polyprotein [71, 120].
In the work of Wondrak et al., 72 amino acid peptide containing one cleavage site was
synthesized to avoid the employment of small peptides [121].
Peptide cleavage assays cannot reveal the relative rates of Gag processing, therefore
the simulation of the native processing event was needed. This was done by cell-free
expression system of full-length Gag polyprotein and the kinetic analysis clarified that
Gag processing by HIV-1 proteinase was an ordered process [70, 71].
In this thesis, we propose to study Gag cleavage kinetics using the full-length substrate.
Several studies of Gag polyprotein utilized the product with truncation in the N-terminal
MA domain or C-terminal p6 domain in order to disrupt the Gag aggregation [122, 123].
Carlson et al. described the expression of the full-length Gag polyprotein [124] using
heparin column in addition to other conventional techniques. In our study, we prepared
three His- and MBP-tagged full-length Gag polyprotein variants (Gag-MBP, HisGag-MBP,
Gag-MBPHis). The MBP tag provides protection of C-terminal p6 domain and it allows
us to separate the target protein from its degradation products, which result from the
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Gag cleavage within the p6 region by bacterial proteinases during the expression and
purification process. Furthermore, MBP improves the solubility of the protein and can
be used for purification on amylose column, although it was finally not used in this work.
In the kinetic assay, where the sequence and rate of individual cleavages is studied, the
fusion protein allows us to observe also the C-terminal cleavage products by SDS-PAGE,
which are otherwise short and hardly visible.
All three constructs were cloned and expressed in E.coli. HisGag-MBP variant was
purified and used in kinetic experiments with the wild-type HIV-1 proteinase. Because
Gag precipitates in imidazole-free buffer, 50 mM imidazole in each cleavage reaction was
present to stabilize the substrate. The originally basic pH was adjusted to 4.4 by the
addition of acidic acetate buffer in order to reach the optimum conditions for PR cleavage.
The PR activity was verified by spectroscopic assay using chromogenic peptide substrate.
We analyzed the cleavage products by SDS-PAGE and Western blotting using anti-
bodies against capsid and matrix proteins. We are able to observe the p2↓NC cleavage
by the wild-type PR. The products are visible after 1 h, and than they are cleaved to
final structural proteins. The cleavage at MA↓CA and p2↓NC is visible on the gel and
blot as the gradual increase of MA and CA proteins over time. The other cleavages are
difficult to be observed by these methods. The p1↓p6 cleavage can be seen on the gels, but
the products are not well stainable, therefore it is not possible to evaluate the kinetics.
The NC↓p1 cleavage cannot be observed at all, as the products are small and invisible on
the gel. Both these processes would be better observable with the eventual use of anti-
nucleocapsid antibody, which was currently inaccessible to us. The most questionable
point is the CA↓p2 cleavage. As the detection of the proteins by the anti-capsid anti-
body is highly sensitive, a double band of 2 kDa difference of bands can be expected as a
consequence of this cleavage. However, only a single band is observed on all the gels and
blots. This can be explained either by a small mobility difference of the two proteins or,
as the observed bands correspond well with the CA standard, by very high rate of the PR
cleavage. However, rates of this cleavage are generally slow [71], therefore the latter option
seems less likely. This question can be resolved by the method of mass spectrometry.
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Furthermore, the cleavage experiments within this diploma thesis are carried out with
the purified HisGag-MBP that contains a minor degradation product that has not been
completely removed in the purification process. The product can be seen in the non-
processed Gag at 0 h and in all the control reactions. As it is detected only by the
anti-matrix antibody and its molecular weight is slightly higher than that of MA, it seems
to be MA protein extended by a short part of CA. This idea is confirmed also by the fact
that the band of this protein vanishes during the proteolytic cleavage by HIV-1 PR and
changes most likely to the MA and a short peptide invisible on the blot. However, the
total amount of this degradation product is likely very low because it is not visible on SDS-
PAGE gel, but only on the very sensitive blot with anti-matrix antibody. Nevertheless,
the presence of this band does not complicate the interpretation of the kinetic experiments
remarkably.
We observe also the influence of the mutations in proteinase on the rate and order of
Gag processing. We have chosen drv6 HIV-1 PR [119], that has the twenty-one mutations
and thus its activity varies from that of the wild-type HIV-1 PR. The simultaneously
carried out reactions with both wild-type and mutant PR show, that the mutated PR
processes Gag with decreased rate, but the decrease is not equal for all the cleavage sites.
The first cleavage between the p2 and NC peptides runs in both cases with relatively high
velocity. Full-length Gag is almost completely processed after 1 h, although in the case
of the mutant proteinase the process seems to be somewhat slower. The most significant
difference can be observed at the second cleavage between MA and CA proteins. Although
the cleavage by wild-type PR is observable already after 1 h and is almost complete after 5
h, cleavage by the mutant variant of PR is barely visible after 5 and 10 h and a substantial
portion of MA-CA-p2 substrate is processed only after 24 h. Thus, this cleavage site is
probably more sensitive to the structural changes induced by individual mutations than
the p2↓NC site. This indicates that this cleavage can make the considerable difference in
the life-cycle periods of the wild-type and mutated virus. Hence, it is conceivable that the
purpose of the subsequent mutations in the Gag cleavage sites is to compensate the rate
decrease rather than to force the inhibitor out of the active-site cavity of PR [111, 112].
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The reason is that the enzyme-inhibitor affinity is so high that a structural rearrangement
of the substrate would have to be improbably efficient in order to influence this equilibrium
considerably. However, this assumption has to be confirmed by additional experiments
with the mutated Gag polyprotein. These experiments were originally planned for this
thesis, but they had to be postponed, because the clone of the mutated Gag has not been
delivered to us by the collaborating foreign laboratory in time.
This experiment represents the background to assess the dependence of cleavage rates
for individual mutations in HIV-1 proteinase. We plan to carry out the experiments with
more mutant variants of HIV-1 PR that are present in our laboratory. Furthermore,
the role of mutations in Gag polyprotein should be studied, therefore a production of
several Gag variants will be necessary, which will be used in the kinetic assays with the
wild-type and mutant HIV-1 PR. This should provide a better insight into the process of
mutagenesis of HIV virus under the selection pressure of inhibitors and help us to elucidate
the causative relations among the development of mutation in different viral proteins and
their specific sites.
Although the presented study describes a way how to determine the cleavage kinetics
of Gag processing by PR, a reliable quantitative statement cannot be obtained from it.
Therefore, further analysis by more sophisticated methods are planned for the future
continuation of these experiments. The method of capillary electrophoresis in the regime
of capillary gel electrophoresis represents a suitable choice. Here, the capillary is filled by
polyacrylamide solution and the separation is performed in the presence of SDS, therefore
the method is a direct analogy of SDS-PAGE, which enables us an easy interpretation.
Another alternative is LC/MS, i.e. the HPLC separation of cleavage products followed by
both UV and MS detection. The advantage of this technique is the unambiguous detection
of the products, but, on the contrary, the optimization of this method for simultaneous
separation of all the products can be a more complex problem. Both the methods have
already been applied to our samples, but reproducible results have not been obtained from
either of them yet due to the lack of time. Therefore, these experiments are not reported
in this thesis, but they are planned to be carried out in the future.
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Conclusion
To study the Gag processing by HIV-1 proteinase, the recombinant full-length Gag polypro-
tein that represents the natural substrate is needed. For this purpose, three C-terminally
MBP-tagged Gag variants (Gag-MBP, HisGag-MBP and Gag-MBPHis) were cloned into
expression vector pET22b and recombinantly expressed in E.coli BL21(DE3)RIL. HisGag-
MBP was purified with the yield of 1 mg/l of bacterial culture. HisGag-MBP was cleaved
by both the wild-type and mutant HIV-1 proteinase and the cleavage products were ana-
lyzed via SDS-PAGE and Western blotting. Substantial decrease have been observed for
the cleavage rate of Gag by wild-type HIV-1 PR in comparison with the mutant variant,
especially for the MA↓CA site. This indicates that the subsequently developed mutations
in the cleavage sites may serve the virus to compensate this rate decrease.
Although not all originally defined goals have been achieved, this diploma thesis rep-
resents a background to study Gag processing in more detail using a natural substrate.
For future experiments, the optimization of Gag purification will be needed to obtain pure
and stable protein. The products of Gag cleavage by PR will be analyzed by quantitative
methods like LC/MS or capillary electrophoresis. In order to complete the study, it is
planned to analyze the influence of mutations in Gag polyprotein on PR cleavage and
thus to evaluate their effect on HIV resistance.
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S.A. Galpin, B.K. Handa, J. Kay, A. Kröhn, R.W. Lambert, J.H. Merrett, J.S. Mills,
K.E. Parkes, S. Redshaw, A.J. Ritchie, D.L. Taylor, G.J. Thomas, and P.J. Machin.
Rational Design of Peptide-Based HIV Proteinase. Science, 248:358–361, 1990.
[75] A. Wlodawer. Rational approach to AIDS drug design through structural biology.
Annu Rev Med, 53(6):595–614, 2002.
[76] D.J. Kempf, K.C. Marsh, L.C. Fino, P. Bryant, A. Craig-Kennard, H.L. Sham,
C. Zhao, S. Vasavanonda, W.E. Kohlbrenner, N.E. Wideburg, A. Saldivar, B.E.
Green, T. Herrin, and D. Norbeck. Design of orally bioavailable, symmetry-based
inhibitors of HIV protease. Bioorgan Med Chem, 2(9):847–858, 1994.
69
[77] G.N. Kumar, A.D. Rodrigues, A.M. Buko, and J.F. Denissen. Cytochrome P450-
mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human
liver microsomes. J Pharmacol Exp Ther, 277(1):423–431, 1996.
[78] B.D. Dorsey, R.B. Levin, S.L. McDaniel, J.P. Vacca, J.P. Guare, P.L. Darke, J.A.
Zugay, E.A. Emini, and W.A. Schleif. L-735,524: the design of a potent and orally
bioavailable HIV protease inhibitor. J Med Chem, 37(21):3443–3451, 1994.
[79] A.K. Patick, H. Mo, M. Markowitz, K. Appelt, B. Wu, L. Musick, S. Kaldor,
S. Reich, D.D. Ho, and S. Webber. Antiviral and resistance studies of AG1343 ,
an orally bioavailable inhibitor of human immunodeficiency virus protease. Antimi-
crob Agents Ch, 40(2):292–297, 1996.
[80] E.E. Kim, C.T. Baker, M.D. Dwyer, M.A. Murcko, B.G. Rao, R.D. Tung, and M.A.
Navia. Crystal structure of HIV-1 protease in complex with VX-478, a potent and
orally bioavailable inhibitor of the enzyme. J Am Chem Soc, 117(3):1181–1182, 1995.
[81] P. Vierling and J. Greiner. Prodrugs of HIV protease inhibitors. Curr Pharm Design,
9(22):1755–1770, 2003.
[82] E. De Clercq. New developments in anti-HIV chemotherapy. Biochim Biophys Acta,
1587(2-3):258–275, 2002.
[83] S.M. Poppe, D.E. Slade, K.-T. Chong, R.R. Hinshaw, P.J. Pagano, M. Markowitz,
D.D. Ho, H. Mo, R.R. Gorman, T.J. Dueweke, S. Thaisrivongs, and W.G. Tarpley.
Antiviral activity of the dihydropyrone PNU-140690 , a new nonpeptidic human
immunodeficiency virus protease inhibitor. Antimicrob Agents Ch, 41(5):1058–1063,
1997.
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